author-photo

Philippe Aftimos

Université libre de Bruxelles
Institut Jules Bordet

152

Papers

1527

Citations

Citation Trend

Filter By

Papers (107) Sort By

Journal Conference Others

Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations

2021 The Breast
Show All
- Source
- Cite
- Save
Citations (0)
Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative.

2021 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (4)
Factors associated with SARS-CoV-2 infection and outcome in patients with solid tumors or hematological malignancies: a single-center study.

2021 Supportive Care in Cancer
Show All
- Source
- Cite
- Save
Citations (2)
FUS-CREM-rearranged malignant epithelioid neoplasm mimicking neuroendocrine neoplasm of unknown primary.

2021 Histopathology
Show All
- Source
- Cite
- Save
Citations (0)
Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PD8-07: Pharmacodynamic analysis from a phase 1 study of rintodestrant (G1T48), an oral selective estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
The NHance ® Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.

2021 Biomedicines
Show All
- Source
- Cite
- Save
Citations (0)
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (3)
Abstract PS12-04: Rintodestrant (G1T48), an oral selective estrogen receptor degrader in ER+/HER2- locally advanced or metastatic breast cancer: Updated phase 1 results and dose selection

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)